You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Brigatinib

Showing 1 - 25 of 35
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Volunteers Trial in Tempe (Brigatinib)

Not yet recruiting
  • Healthy Volunteers
  • Brigatinib
  • Tempe, Arizona
    Celerion, Inc.
Nov 10, 2023

Information Available in Chinese Non-Small-cell Lung Cancer

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Brigatinib
  • Shanghai, Shanghai, China
    Department of Oncology, Shanghai pulmonary hospital
Feb 1, 2023

d To Treat People With Non-Small Cell Lung Cancer

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Brigatinib
  • Tokyo, Japan
    Takeda Selected Site
Oct 13, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Brigatinib
  • Paris, France
  • +1 more
Sep 27, 2022

NSCLC Trial in United States (brigatinib)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • brigatinib
  • Denver, Colorado
  • +3 more
Jan 10, 2023

Usage of Brigatinib in Treatment of Adult Approved Indications

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Anaplastic Lymphoma Kinase
  • No Intervention
  • Busan, Korea, Republic of
    Pusan National University Hospital
Oct 19, 2022

Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Brigatinib
  • Goyang-si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC Trial in Seoul (Brigatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Brigatinib
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Apr 29, 2022

NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

Not yet recruiting
  • NSCLC, Stage III
  • ALK-rearrangement
  • Angers, France
  • +19 more
Feb 8, 2023

Brain Metastases, Lung Cancer Trial in Duarte, Aurora, Rochester (Brigatinib)

Active, not recruiting
  • Brain Metastases
  • Lung Cancer
  • Brigatinib
  • Duarte, California
  • +2 more
Feb 8, 2022

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Brigatinib
  • Tyrosine kinase inhibitor
  • Berlin, Germany
  • +25 more
Nov 10, 2022

Non Small Cell Lung Cancer, ALK Gene Mutation Trial in France (Brigatinib 180 MG, Carboplatin, Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • ALK Gene Mutation
  • Brigatinib 180 MG
  • +2 more
  • Angers, France
  • +31 more
Aug 9, 2022

Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No intervention
  • Bydgoszcz, Poland
  • +11 more
Feb 22, 2023

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Brigatinib
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1

Completed
  • Lung Cancer ROS Translocated
    • Créteil, France
      CHI Créteil
    Nov 19, 2021

    Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

    Recruiting
    • Locally Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Bevacizumab
    • Brigatinib
    • Duarte, California
    • +4 more
    Aug 17, 2022

    Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Oslo, Norway
      Pfizer Norway
    Apr 17, 2023

    Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary

    Active, not recruiting
    • Non-Small Cell Lung Cancer
      • Aurora, Colorado
      • +4 more
      Jan 21, 2022

      Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

      Completed
      Has Results
      • Lymphoma, Large-Cell, Anaplastic
      • Carcinoma, Non-Small-Cell Lung
      • Brigatinib
      • (no location specified)
      Jul 26, 2021

      ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

      Completed
      Has Results
      • ALK-positive NSCLC
      • Sollentuna, Sweden
        Pfizer Innovations AB
      Mar 14, 2022

      free Survival and Evaluate Participant Experience for Metastatic

      Active, not recruiting
      • Anaplastic Lymphoma Kinase-positive
      • Carcinoma Non-small-cell Lung
      • Brigatinib
      • +4 more
      • Maynard, Massachusetts
        EmpiraMed, Inc.
      Feb 28, 2022

      Anaplastic Large Cell Lymphoma, ALK-Positive Trial in Philadelphia (Brigatinib)

      Withdrawn
      • Anaplastic Large Cell Lymphoma, ALK-Positive
      • Brigatinib
      • Philadelphia, Pennsylvania
        Fox Chase Cancer Center
      Jan 4, 2021

      NSCLC Trial (Brigatinib)

      Completed
      Has Results
      • Carcinoma, Non-Small-Cell Lung
      • Brigatinib
      • (no location specified)
      Feb 18, 2021

      Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Tumor, Advanced ALK+ or ROS1+Solid Tumors Trial in Worldwide (Midazolam,

      Completed
      • Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
      • Paris, Ile-de-france, France
      • +13 more
      May 19, 2021

      ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

      Active, not recruiting
      Has Results
      • ALK-positive Advanced NSCLC
      • Brigatinib
      • Orange, California
      • +79 more
      Nov 15, 2022